The Best FDA Decision On Peptide Authorization Isn’t Yes Or No
The Best FDA Decision On Peptide Authorization Isn't Yes Or No The Food and Drug Administration's approach to regulating therapeutic peptides has reached an inflection point, and according to a recent analysis published by Forbes, the most consequential path forward for the agency may not be a simp...
Read Full ArticleAll News
Phoenix doctor urges caution as FDA moves to regulate popular peptides
Phoenix Doctor Urges Caution as FDA Moves to Regulate Popular Peptides A Phoenix-based physician is warning consumers to exercise caution amid growing regulatory scrutiny of peptide therapies, as the U.S.
FDA issues warning letters to five unapproved GLP-1 websites
FDA Issues Warning Letters to Five Unapproved GLP-1 Websites The U.S. Food and Drug Administration has issued warning letters to five websites for allegedly marketing unapproved versions of GLP-1 receptor agonist products, according to a report from pharmaphorum.com.
FDA cracks down on online black market for weight loss peptides
FDA Targets Illicit Online Sales of Weight Loss Peptides Amid Surging Demand The U.S. Food and Drug Administration is intensifying scrutiny of an expanding online black market for weight loss peptides, according to a report from Pharmaceutical Technology.
Aurobindo Pharma’s Auropeptides US FDA Inspection Ends With One Finding
Aurobindo Pharma's Peptide Manufacturing Unit Clears FDA Inspection With Single Observation Aurobindo Pharma's specialized peptide manufacturing subsidiary, Auropeptides, has concluded a US Food and Drug Administration inspection with only one observation noted, according to a report by Sahi.
Hims Stock Slips Overnight As FDA Warns Telehealth Firms Over GLP-1 Claims — Why Traders Think The ‘Overhang’ Won’t Last
Hims & Hers Shares Dip as FDA Signals Scrutiny of GLP-1 Marketing by Telehealth Providers Shares of Hims & Hers Health slipped in overnight trading after reports emerged that the U.S.
The FDA Is Right to Prohibit Mass Production of Unapproved GLP-1 Drugs
FDA Is Right to Prohibit Mass Production of Unapproved GLP-1 Drugs, Legal Experts Say The Food and Drug Law Institute (FDLI) has weighed in on one of the most contentious regulatory disputes in pharmaceutical law today, arguing that the Food and Drug Administration's efforts to curb mass production...
5 Things to Know About the FDA's Peptide Reversal
FDA's Shifting Stance on Peptides Sends Ripples Through Compounding Industry The U.S.
FDA Advisory Committee Voted Yes on Six Peptides. Now What? The Regulatory Road Ahead
FDA Advisory Committee Voted Yes on Six Peptides.
July 27, 2026: FDA peptide panel narrowly votes to add unapproved drugs to compounding list
FDA Advisory Panel Narrowly Approves Adding Unapproved Peptides to Compounding List A Food and Drug Administration advisory panel voted narrowly on July 27, 2026, to recommend adding certain unapproved peptide drugs to the agency's compounding lists, according to reporting from the Partnership for ...
FDA on Peptides: A New Landscape for Compounders
FDA on Peptides: A New Landscape for Compounders Washington, D.C.
An FDA Advisory Panel Voted to Ease Restrictions on 6 Controversial Peptides—Here’s What That Means
FDA Advisory Panel Reportedly Backs Loosening Restrictions on Six Contested Peptides A Food and Drug Administration advisory panel has reportedly voted in favor of easing restrictions on six peptides that have been at the center of an ongoing regulatory dispute, according to a report from Allure.
Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides
Above the Federal Floor: How States Are Regulating Compounded GLP-1s and Peptides State legislatures and pharmacy boards across the country are moving to impose their own restrictions on compounded GLP-1 medications and peptide products, adding a new layer of regulatory complexity for an industry t...
Are Peptides Illegal in California? State Laws Explained
Are Peptides Illegal in California? What the Current Rules Actually Say Confusion over the legal status of therapeutic peptides — from BPC-157 to CJC-1295 and semaglutide-adjacent compounds — has intensified as more Californians turn to wellness clinics, telehealth providers, and compounding ph...
Texas Peptide Laws 2024: Regulations for BPC-157, TB-500, and More
Texas Peptide Laws 2024: What Residents and Businesses Need to Know About BPC-157, TB-500, and Compounded Peptide Therapies As interest in peptide therapies such as BPC-157 and TB-500 continues to grow among Texas consumers, wellness clinics, and compounding pharmacies, questions about the state's ...
FDA panel supports broadening access to peptides popular on the gray market
FDA Advisory Panel Signals Openness to Expanding Legal Access to Popular Peptide Compounds A Food and Drug Administration advisory panel has expressed support for broadening legitimate access to certain peptide compounds that have gained significant popularity through gray-market channels, accordin...
How the FDA Regulates Peptides
How the FDA Regulates Peptides: A Growing Regulatory Gray Zone Under Scrutiny The Food and Drug Administration's oversight of peptide-based products has come under renewed examination, as a new analysis from the Johns Hopkins Bloomberg School of Public Health lays out the complex and often confusin...
FDA staff and peptide enthusiasts set to clash at advisory panel
FDA Advisory Panel Set to Weigh In on Contested Peptide Compounds Amid Growing Industry Tension A forthcoming Food and Drug Administration advisory committee meeting is expected to become a flashpoint in the ongoing debate over the regulatory status of popular research and wellness peptides, accord...
FDA’s Review Of Peptides Signals A Growing Public Health Challenge—Separating Science From Hype
FDA's Review Of Peptides Signals A Growing Public Health Challenge—Separating Science From Hype A recent Forbes report has drawn renewed attention to the Food and Drug Administration's ongoing scrutiny of the peptide industry, highlighting what the publication frames as a growing public health ch...
FDA panel backs 6 peptides despite its own scientists’ objections
FDA Panel Backs Six Peptides Despite Internal Scientific Objections A Food and Drug Administration advisory panel has voted to support the use of six peptide compounds for compounding, moving forward despite documented objections from the agency's own scientific staff, according to a report from Ma...
FDA puts former Rancho Santa Fe pharmacist on notice for selling unapproved weight-loss injections online
FDA Targets Former Rancho Santa Fe Pharmacist Over Online Weight-Loss Injection Sales The U.S.